The Supreme Court’s decision to review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. places renewed attention on a ...
On January 16, 2026, the U.S. Supreme Court agreed to hear Hikma Pharmaceuticals USA, Inc. v. Amarin Pharma, Inc., a patent ...
DOJ accuses Louisiana AG, alleged victim of abortion coercion of trying to "short circuit" FDA's review of mifepristone's ...
WASHINGTON, Jan 16 (Reuters) - The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic ...
The U.S. Supreme Court has decided to hear a case between Amarin Pharma and generic drugmaker Hikma that puts so-called ...
On Friday, the U.S. Supreme Court granted certiorari to a petition filed by patent owner Hikma Pharmaceuticals, taking up Hikma’s appeal of the U.S. Court of Appeals for the Federal Circuit’s ruling ...
Shares of Bayer AG BAYRY gained 6.41% on Jan. 19, after the company announced that the Supreme Court agreed to review the ...
11d
Can Texas enforce immigration law on its own? Appeals court hears legal challenge to Senate Bill 4.
The fate of a Texas law that makes it a crime to enter the country without authorization could hinge on who has the right to ...
At a Glance The FDA reversed its 2022 NMN ban in September 2025, allowing the $500 million ingredient back on the market ...
The Senate Committee on Health, Education, Labor and Pensions (HELP) is holding a hearing Wednesday morning focused on mifepristone, one of two abortion pills approved by the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results